---
authors:
- Ebell, Mark H
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/38804769/
file_path: 2024/05/single-intramuscular-dose-of-nirsevimab-reduces-likelihood-o.md
issue: '5'
keywords:
- Respiratory
- Infant
- Humans
- Infant, Newborn
- Antibodies, Monoclonal, Humanized
- Injections, Intramuscular
- Antiviral Agents
- Hospitalization
- Female
- Respiratory Syncytial Virus Infections
- Male
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Respiratory Syncytial Virus Infections
- Infant
- Hospitalization
- Injections, Intramuscular
- Male
- Female
- Antiviral Agents
- Infant, Newborn
- Antibodies, Monoclonal, Humanized
original_format: PubMed
pages: 477-478
patient_population: Pediatric
peer_reviewed: true
pmid: '38804769'
processed_date: '2025-07-30'
publication_date: '2024-05-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-10'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- family-practice
- clinical-medicine
- clinical-trial
- pubmed-enhanced
title: Single Intramuscular Dose of Nirsevimab Reduces Likelihood of Hospitalization
  Due to RSV in Average-Risk Infants During First Year of Life.
topics:
- Respiratory Disorders
- Family Medicine
- Pulmonology
volume: '109'
publication_types: &id001
- Journal Article
- Randomized Controlled Trial
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '38804769'
  title: Single Intramuscular Dose of Nirsevimab Reduces Likelihood of Hospitalization
    Due to RSV in Average-Risk Infants During First Year of Life.
  authors:
  - last_name: Ebell
    fore_name: Mark H
    initials: MH
    affiliation: Professor, University of Georgia, Athens, Ga.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '109'
    issue: '5'
  publication_info:
    year: '2024'
    month: '05'
    full_date: '2024-05-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Respiratory Syncytial Virus Infections
    major_topic: true
    qualifiers:
    - qualifier: prevention & control
      major_topic: false
  - descriptor: Infant
    major_topic: false
  - descriptor: Hospitalization
    major_topic: true
    qualifiers:
    - qualifier: statistics & numerical data
      major_topic: false
  - descriptor: Injections, Intramuscular
    major_topic: false
  - descriptor: Male
    major_topic: false
  - descriptor: Female
    major_topic: false
  - descriptor: Antiviral Agents
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
    - qualifier: administration & dosage
      major_topic: false
  - descriptor: Infant, Newborn
    major_topic: false
  - descriptor: Antibodies, Monoclonal, Humanized
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
    - qualifier: administration & dosage
      major_topic: false
  publication_types: *id001
related_articles:
- pmid: '38804769'
  title: Single Intramuscular Dose of Nirsevimab Reduces Likelihood of Hospitalization
    Due to RSV in Average-Risk Infants During First Year of Life.
  authors:
  - name: Ebell MH
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2024 May
- pmid: '32726528'
  title: Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
  authors:
  - name: Griffin MP
    authtype: Author
    clusterid: ''
  - name: Yuan Y
    authtype: Author
    clusterid: ''
  - name: Takas T
    authtype: Author
    clusterid: ''
  - name: Domachowske JB
    authtype: Author
    clusterid: ''
  - name: Madhi SA
    authtype: Author
    clusterid: ''
  - name: Manzoni P
    authtype: Author
    clusterid: ''
  - name: Simões EAF
    authtype: Author
    clusterid: ''
  - name: Esser MT
    authtype: Author
    clusterid: ''
  - name: Khan AA
    authtype: Author
    clusterid: ''
  - name: Dubovsky F
    authtype: Author
    clusterid: ''
  - name: Villafana T
    authtype: Author
    clusterid: ''
  - name: DeVincenzo JP
    authtype: Author
    clusterid: ''
  - name: Nirsevimab Study Group
    authtype: CollectiveName
    clusterid: ''
  source: N Engl J Med
  pubdate: 2020 Jul 30
- pmid: '35235726'
  title: Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
  authors:
  - name: Hammitt LL
    authtype: Author
    clusterid: ''
  - name: Dagan R
    authtype: Author
    clusterid: ''
  - name: Yuan Y
    authtype: Author
    clusterid: ''
  - name: Baca Cots M
    authtype: Author
    clusterid: ''
  - name: Bosheva M
    authtype: Author
    clusterid: ''
  - name: Madhi SA
    authtype: Author
    clusterid: ''
  - name: Muller WJ
    authtype: Author
    clusterid: ''
  - name: Zar HJ
    authtype: Author
    clusterid: ''
  - name: Brooks D
    authtype: Author
    clusterid: ''
  - name: Grenham A
    authtype: Author
    clusterid: ''
  - name: Wählby Hamrén U
    authtype: Author
    clusterid: ''
  - name: Mankad VS
    authtype: Author
    clusterid: ''
  - name: Ren P
    authtype: Author
    clusterid: ''
  - name: Takas T
    authtype: Author
    clusterid: ''
  - name: Abram ME
    authtype: Author
    clusterid: ''
  - name: Leach A
    authtype: Author
    clusterid: ''
  - name: Griffin MP
    authtype: Author
    clusterid: ''
  - name: Villafana T
    authtype: Author
    clusterid: ''
  - name: MELODY Study Group
    authtype: CollectiveName
    clusterid: ''
  source: N Engl J Med
  pubdate: 2022 Mar 3
- pmid: '38701823'
  title: 'Effectiveness and impact of universal prophylaxis with nirsevimab in infants
    against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial
    results of a population-based longitudinal study.'
  authors:
  - name: Ares-Gómez S
    authtype: Author
    clusterid: ''
  - name: Mallah N
    authtype: Author
    clusterid: ''
  - name: Santiago-Pérez MI
    authtype: Author
    clusterid: ''
  - name: Pardo-Seco J
    authtype: Author
    clusterid: ''
  - name: Pérez-Martínez O
    authtype: Author
    clusterid: ''
  - name: Otero-Barrós MT
    authtype: Author
    clusterid: ''
  - name: Suárez-Gaiche N
    authtype: Author
    clusterid: ''
  - name: Kramer R
    authtype: Author
    clusterid: ''
  - name: Jin J
    authtype: Author
    clusterid: ''
  - name: Platero-Alonso L
    authtype: Author
    clusterid: ''
  - name: Alvárez-Gil RM
    authtype: Author
    clusterid: ''
  - name: Ces-Ozores OM
    authtype: Author
    clusterid: ''
  - name: Nartallo-Penas V
    authtype: Author
    clusterid: ''
  - name: Mirás-Carballal S
    authtype: Author
    clusterid: ''
  - name: Piñeiro-Sotelo M
    authtype: Author
    clusterid: ''
  - name: Malvar-Pintos A
    authtype: Author
    clusterid: ''
  - name: González-Pérez JM
    authtype: Author
    clusterid: ''
  - name: Rodríguez-Tenreiro-Sánchez C
    authtype: Author
    clusterid: ''
  - name: Rivero-Calle I
    authtype: Author
    clusterid: ''
  - name: Salas A
    authtype: Author
    clusterid: ''
  - name: Durán-Parrondo C
    authtype: Author
    clusterid: ''
  - name: Martinón-Torres F
    authtype: Author
    clusterid: ''
  - name: NIRSE-GAL study group
    authtype: CollectiveName
    clusterid: ''
  source: Lancet Infect Dis
  pubdate: 2024 Aug
- pmid: '38738683'
  title: Assessment of effectiveness and impact of universal prophylaxis with nirsevimab
    for prevention of hospitalizations due to respiratory syncytial virus in infants.
    The NIRSE-GAL study protocol.
  authors:
  - name: Mallah N
    authtype: Author
    clusterid: ''
  - name: Ares-Gómez S
    authtype: Author
    clusterid: ''
  - name: Pardo-Seco J
    authtype: Author
    clusterid: ''
  - name: Malvar-Pintos A
    authtype: Author
    clusterid: ''
  - name: Santiago-Pérez MI
    authtype: Author
    clusterid: ''
  - name: Pérez-Martínez O
    authtype: Author
    clusterid: ''
  - name: Otero-Barrós MT
    authtype: Author
    clusterid: ''
  - name: Suárez-Gaiche N
    authtype: Author
    clusterid: ''
  - name: Kramer R
    authtype: Author
    clusterid: ''
  - name: Jin J
    authtype: Author
    clusterid: ''
  - name: Platero-Alonso L
    authtype: Author
    clusterid: ''
  - name: Alvárez-Gil RM
    authtype: Author
    clusterid: ''
  - name: Ces-Ozores OM
    authtype: Author
    clusterid: ''
  - name: Nartallo-Penas V
    authtype: Author
    clusterid: ''
  - name: Mirás-Carballal S
    authtype: Author
    clusterid: ''
  - name: Piñeiro-Sotelo M
    authtype: Author
    clusterid: ''
  - name: González-Pérez JM
    authtype: Author
    clusterid: ''
  - name: Rodríguez-Tenreiro C
    authtype: Author
    clusterid: ''
  - name: Rivero-Calle I
    authtype: Author
    clusterid: ''
  - name: Salas A
    authtype: Author
    clusterid: ''
  - name: Durán-Parrondo C
    authtype: Author
    clusterid: ''
  - name: Martinón-Torres F
    authtype: Author
    clusterid: ''
  source: Hum Vaccin Immunother
  pubdate: 2024 Dec 31
---

# Single Intramuscular Dose of Nirsevimab Reduces Likelihood of Hospitalization Due to RSV in Average-Risk Infants During First Year of Life.

**Authors:** Ebell, Mark H

**Published in:** American family physician | Vol. 109, No. 5 | 2024-05-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/38804769/)

## Clinical Information

**Population:** Pediatric | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Respiratory Disorders, Family Medicine, Pulmonology

## MeSH Terms

Humans, Respiratory Syncytial Virus Infections, Infant, Hospitalization, Injections, Intramuscular, Male, Female, Antiviral Agents, Infant, Newborn, Antibodies, Monoclonal, Humanized

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/38804769/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
